Metabolic Syndrome Therapy Targeting Fibroblast Activation Protein [FAP]
A small molecule chemical inhibitor, selective for FAP, has potential for improving glucose tolerance in metabolic syndrome patients.
Metabolic syndrome and its related disorders including diabetes is a massive and growing unsolved health problem that has many therapeutic drugs in use and in development.
Current type 2 diabetes therapies are at best partially effective at alleviating the patients inability to fully control blood glucose levels.
Many therapies have side effects that make them unsuitable for some patients. Some therapies cause weight gain; indeed only the new incretin therapies do not cause weight gain.
This potential therapy, while still not a cure or panacea, would add to the arsenal of safe effective therapies that will not cause weight gain.
Potentially a therapy for type 2 diabetes and pre-diabetic conditions including metabolic syndrome and impaired glucose tolerance.
- Associate Professor Mark Gorrell